Skip to content
10-K

Annual Report

Amylyx Pharmaceuticals, Inc. AMLX

0001193125-26-086645

← back to feed
Filed
Mar 3, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Feb 23, 2026 110.54M sh
Shares Diluted FY 2025 · Dec 31, 2025 94.57M sh
Shares Diluted FY 2025 · Dec 31, 2024 68.14M sh
Capex FY 2025 · Dec 31, 2025 $138K
Capex FY 2025 · Dec 31, 2024 $157K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$123.34M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$167.65M
Cash And Equivalents FY 2025 · Dec 31, 2025 $226.65M
Cash And Equivalents FY 2025 · Dec 31, 2024 $77.39M
Stockholders Equity FY 2025 · Dec 31, 2025 $305.26M
Stockholders Equity FY 2025 · Dec 31, 2024 $164.77M
Stockholders Equity FY 2025 · Dec 31, 2023 $433.43M
Current Liabilities FY 2025 · Dec 31, 2025 $22.69M
Current Liabilities FY 2025 · Dec 31, 2024 $28.41M
Total Liabilities FY 2025 · Dec 31, 2025 $27.39M
Total Liabilities FY 2025 · Dec 31, 2024 $28.87M
Current Assets FY 2025 · Dec 31, 2025 $323.67M
Current Assets FY 2025 · Dec 31, 2024 $189.43M
Total Assets FY 2025 · Dec 31, 2025 $332.65M
Total Assets FY 2025 · Dec 31, 2024 $193.63M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.53
Eps Diluted FY 2025 · Dec 31, 2024 −$4.43
Eps Basic FY 2025 · Dec 31, 2025 −$1.53
Eps Basic FY 2025 · Dec 31, 2024 −$4.43
Sga Expense FY 2025 · Dec 31, 2025 $62.89M
Sga Expense FY 2025 · Dec 31, 2024 $114.33M
Rd Expense FY 2025 · Dec 31, 2025 $90.4M
Rd Expense FY 2025 · Dec 31, 2024 $104.08M
Net Income FY 2025 · Dec 31, 2025 −$144.74M
Net Income FY 2025 · Dec 31, 2024 −$301.74M
Operating Income FY 2025 · Dec 31, 2025 −$153.29M
Operating Income FY 2025 · Dec 31, 2024 −$314.73M
Cost Of Revenue FY 2025 · Dec 31, 2025 $0
Cost Of Revenue FY 2025 · Dec 31, 2024 $5.95M
Revenue FY 2025 · Dec 31, 2025 $0
Revenue FY 2025 · Dec 31, 2024 $87.37M